ArticleScientific reports2019
A multicentre clinical validation of AminoIndex Cancer Screening (AICS).
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Multi-cancer early detection tests for general population screening: a systematic literature review.Health technology assessment (Winchester, England) · 2025Pooled it
- Metabolomic profiling of upper GI malignancies in blood and tissue: a systematic review and meta-analysis.Journal of cancer research and clinical oncology · 2024Pooled it
- Decreased sphingomyelin (t34:1) is a candidate predictor for lung squamous cell carcinoma recurrence after radical surgery: a case-control study.BMC cancer · 2021Pooled it
- Liquid Biopsy-Based Metabolomics in Epithelial Ovarian Cancer: Challenges, Methodological Advances and Translational Considerations.Diagnostics (Basel, Switzerland) · 2026Review
- Machine learning for identifying liver and pancreas cancers through comprehensive serum glycopeptide spectra analysis: a case-control study.Molecular oncology · 2025Article
- Untargeted metabolomics analysis of metabolite changes in gastric cancer patients from plateau regions.World journal of gastrointestinal oncology · 2025Article
- Article
- Comprehensive serum glycopeptide spectrum analysis with machine learning for non-invasive early detection of gastrointestinal cancers.Computational and structural biotechnology journal · 2025Article
- Evaluation of an innovative multi-cancer early detection test: high sensitivity and specificity in differentiating cancer, inflammatory conditions, and healthy individuals.Frontiers in oncology · 2025Article
- Comprehensive serum glycopeptide spectra analysis to identify early-stage epithelial ovarian cancer.Scientific reports · 2024Article
- Tissue and plasma free amino acid detection by LC-MS/MS method in high grade glioma patients.Journal of neuro-oncology · 2023Article
- Development and internal validation of nomograms based on plasma metabolites to predict non-small cell lung cancer risk in smoking and nonsmoking populations.Thoracic cancer · 2023Article
- Lipid biomarkers that reflect postoperative recurrence risk in lung cancer patients who smoke: a case-control study.Lipids in health and disease · 2023Article
- Article
- Alterations in the gastric microbiota and metabolites in gastric cancer: An update review.Frontiers in oncology · 2022Review
- The gut microbiota associated with high-Gleason prostate cancer.Cancer science · 2021Article
- Liquid biopsy as a perioperative biomarker of digestive tract cancers: review of the literature.Surgery today · 2021Review
- Plasma amino acids indicate glioblastoma with ATRX loss.Amino acids · 2021Article
- Article
- Metabolomic Biomarkers for Detection, Prognosis and Identifying Recurrence in Endometrial Cancer.Metabolites · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AminoIndex Cancer Screening (AICS) is a novel cancer screening test based on plasma free amino acid (PFAA) levels. This system categorises subjects as rank A, B, or C in order of increasing probability of each cancer incidence. The current study aimed to validate the potential of AICS for cancer detection. AICS values were determined from the PFAA levels in subjects examined at Chiba Cancer Center Cohort, Mitsui Memorial Hospital, and Saihaku Hospital, and the cancer incidence was investigated. The sensitivities of rank C for cancer diagnosis within 1 year after AICS examination were 83.3% (10/12) for gastric, 50.0% (2/4) for lung, 46.2% (6/13) for colorectal, 50.0% (8/16) for prostate, 43.8% (7/16) for breast, and 50.0% (1/2) for uterine/ovarian cancer. The total cancer detection rate via AICS was 0.33% (34/10,245). The sensitivities during the maximum follow-up period of 6.2 years were 51.7% (15/29) for gastric, 18.2% (2/11) for lung, 28.6% (8/28) for colorectal, 36.4% (8/22) for prostate, 29.0% (9/31) for breast, and 33.3% (2/6) for uterine/ovarian cancers. In conclusion, AICS is a more useful method for evaluating the probability of cancer incidence than for predicting onset, suggesting that annual AICS should be recommended to detect any malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.